COYA

Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary medicines to modulate the function of regulatory T cells (Tregs) for treatment of autoimmune, neurodegenerative, and inflammatory diseases. Headquartered in Houston, Texas, the company's lead programs target conditions including amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and Alzheimer's disease. Coya's therapeutic approach focuses on enhancing Treg function to restore immune homeostasis and reduce inflammation. The company's pipeline includes combination biologic therapies designed to expand and activate Tregs in diseased tissues.